AstraZeneca and Pfizer: What are the side effects of Australia’s vaccines? People under 55, women and those previously infected with COVID-19 are more likely to report side effects after receiving either vaccine, according to new research.
Over-50s can now get their COVID vaccine: What do they need to know? Amid reports of blood clots and increasing vaccine hesitancy, patients will likely have questions as the next phase of the rollout gets underway.
No evidence that recent blood clot deaths were linked to COVID vaccine The TGA has confirmed there is ‘no likely association’ between the deaths of two NSW men and the AstraZeneca vaccine.
GPs with AstraZeneca stockpile turn attention to vaccinating over-50s Patient concerns around the AstraZeneca vaccine have seen a decline in interest in some practices, prompting GPs to bring forward the new rollout strategy’s commencement date.
Numbers confirm GPs are the ‘backbone’ of COVID vaccine rollout Australia’s GPs have now administered more than 1.05 million vaccine doses – more than half the rollout’s total of 2.03 million.
Benefits of AstraZeneca overwhelmingly high despite increased clotting risk New European research has found the risk of a rare blood clotting syndrome associated with the vaccine is double what has been previously reported.
Growing number of Australians reject COVID vaccination Vaccine hesitancy has soared since recommendations shifted from AstraZeneca to Pfizer for under-50s.
Mother’s meningococcal grief a powerful reminder for the importance of routine immunisations Kirsty McGinty is sharing her daughter’s story to encourage people to stay on top of routine immunisations, with COVID-19 resulting in many being delayed or missed.
GPs set to receive more AstraZeneca doses in fast-tracked rollout The shift means people over 50 will have access to COVID vaccines from GP respiratory clinics from 3 May, and general practices from 17 May.
Blood clot case under investigation following Pfizer vaccine The news comes as Australia moves to establish local mRNA manufacturing capacity and experts call for current Pfizer supplies to be redirected to younger cohorts.